{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:56:40Z","timestamp":1773867400232,"version":"3.50.1"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["806776"],"award-info":[{"award-number":["806776"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s41669-025-00621-y","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:45:59Z","timestamp":1765874759000},"page":"229-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Use of Health State Utility Values in Cost-Utility Analyses of Selected Infectious Diseases in Aging Populations: A Systematic Review and Critical Appraisal"],"prefix":"10.1007","volume":"10","author":[{"given":"Thi Hao","family":"Pham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovan","family":"Mihajlovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Loncar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ba Khuong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Zeevat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh An","family":"Pham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrham","family":"Wondimu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Meszaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-1191","authenticated-orcid":false,"given":"Jurjen","family":"van der Schans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"621_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jval.2016.06.003","volume":"19","author":"KM Kuntz","year":"2016","unstructured":"Kuntz KM. Decision modeling for cost-utility analysis. Value Health. 2016;19:700\u20131. https:\/\/doi.org\/10.1016\/j.jval.2016.06.003.","journal-title":"Value Health"},{"key":"621_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.004","author":"J Brazier","year":"2019","unstructured":"Brazier J, Ara R, Azzabi I, Busschbach J, Chevrou-S\u00e9verac H, Crawford B, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health. 2019. https:\/\/doi.org\/10.1016\/j.jval.2019.01.004.","journal-title":"Value Health"},{"key":"621_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5\u201321. https:\/\/doi.org\/10.1093\/bmb\/ldq033.","journal-title":"Br Med Bull"},{"key":"621_CR4","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jval.2016.06.001","volume":"19","author":"SE Wolowacz","year":"2016","unstructured":"Wolowacz SE, Briggs A, Belozeroff V, Clarke P, Doward L, Goeree R, et al. Estimating health-state utility for economic models in clinical studies: an ISPOR good research practices task force report. Value Health. 2016;19:704\u201319. https:\/\/doi.org\/10.1016\/j.jval.2016.06.001.","journal-title":"Value Health"},{"key":"621_CR5","unstructured":"Papaioannou D, Brazier J, Paisley S. NICE DSU technical support document 9: The identification, review and synthesis of health state utility values from the literature [Internet]. National Institute for Health and Care Excellence (NICE), London; 2010. http:\/\/europepmc.org\/abstract\/MED\/28481496"},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/0272989X211004532","volume":"41","author":"T Zhou","year":"2021","unstructured":"Zhou T, Chen Z, Li H, Xie F. Using published health utilities in cost-utility analyses: discrepancies and issues in cardiovascular disease. Med Decis Making. 2021;41:685\u201392. https:\/\/doi.org\/10.1177\/0272989X211004532.","journal-title":"Med Decis Making"},{"key":"621_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s10549-017-4283-8","volume":"164","author":"V Nerich","year":"2017","unstructured":"Nerich V, Saing S, Gamper E-M, Holzner B, Pivot X, Viney R, et al. Critical appraisal of health-state utility values used in breast cancer-related cost\u2013utility analyses. Breast Cancer Res Treat. 2017;164:527\u201336. https:\/\/doi.org\/10.1007\/s10549-017-4283-8.","journal-title":"Breast Cancer Res Treat"},{"key":"621_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/0272989X0102100404","volume":"21","author":"CM Bell","year":"2001","unstructured":"Bell CM, Chapman RH, Stone PW, Sandberg EA, Neumann PJ. An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses. Med Decis Making. 2001;21:288\u201394. https:\/\/doi.org\/10.1177\/0272989X0102100404.","journal-title":"Med Decis Making"},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jval.2022.09.2478","volume":"26","author":"I Buchholz","year":"2023","unstructured":"Buchholz I, Janssen MF. EQ-5D-3L norms for the European older population: country-specific norms for 15 European countires based on the survey of health, ageing, and retirement in Europe. Value Health. 2023;26:721\u201332. https:\/\/doi.org\/10.1016\/j.jval.2022.09.2478.","journal-title":"Value Health"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1186\/s12879-017-2801-2","volume":"17","author":"J Yang","year":"2017","unstructured":"Yang J, Jit M, Zheng Y, Feng L, Liu X, Wu JT, et al. The impact of influenza on the health related quality of life in China: an EQ-5D survey. BMC Infect Dis. 2017;17:686. https:\/\/doi.org\/10.1186\/s12879-017-2801-2.","journal-title":"BMC Infect Dis"},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ British Medical Journal Publishing Group. 2021;372:71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ. British Medical Journal Publishing Group"},{"key":"621_CR12","unstructured":"Executive Board 146. Decade of healthy ageing: development of a proposal for a decade of healthy ageing 2020\u20132030: report by the Director-General [Internet]. World Health Organization, Geneva, 2020. https:\/\/iris.who.int\/handle\/10665\/356347"},{"key":"621_CR13","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1016\/j.vaccine.2018.08.041","volume":"36","author":"S Esposito","year":"2018","unstructured":"Esposito S, Principi N, Rezza G, Bonanni P, Gavazzi G, Beyer I, et al. Vaccination of 50+ adults to promote healthy ageing in Europe: the way forward. Vaccine. 2018;36:5819\u201324. https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.041.","journal-title":"Vaccine"},{"key":"621_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18332\/popmed\/163244","volume":"5","author":"SD Whang","year":"2023","unstructured":"Whang SD, Yim V, Cabrera M, Moore M, Lomazzi M. Implementing older adult vaccination within the Immunization Agenda 2030: a discussion of potential challenges and solutions. Popul Med. 2023;5:1\u20135. https:\/\/doi.org\/10.18332\/popmed\/163244.","journal-title":"Popul Med"},{"key":"621_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00118","author":"M Esme","year":"2019","unstructured":"Esme M, Topeli A, Yavuz BB, Akova M. Infections in the elderly critically-ill patients. Front Med. 2019. https:\/\/doi.org\/10.3389\/fmed.2019.00118.","journal-title":"Front Med"},{"key":"621_CR16","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1017\/S0950268820000400","volume":"148","author":"M Tin Tin Htar","year":"2020","unstructured":"Tin Tin Htar M, Yerramalla MS, Mo\u00efsi JC, Swerdlow DL. The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis. Epidemiol Infect. 2020;148:e48. https:\/\/doi.org\/10.1017\/S0950268820000400.","journal-title":"Epidemiol Infect"},{"key":"621_CR17","doi-asserted-by":"publisher","first-page":"18771","DOI":"10.1038\/s41598-023-46079-y","volume":"13","author":"SM Aljunid","year":"2023","unstructured":"Aljunid SM, Mad Tahir NS, Ismail A, Abdul Aziz AF, Azzeri A, Zafirah SA, et al. Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia. Sci Rep. 2023;13:18771. https:\/\/doi.org\/10.1038\/s41598-023-46079-y.","journal-title":"Sci Rep"},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta7240","volume":"7","author":"S Allsup","year":"2003","unstructured":"Allsup S, Gosney M, Haycox A, Regan M. Cost-benefit evaluation of routine influenza immunisation in people 65-74 years of age. Health Technol Assess. 2003;7:iii\u2013x, 1\u201365. https:\/\/doi.org\/10.3310\/hta7240.","journal-title":"Health Technol Assess"},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1016\/j.vaccine.2024.04.002","volume":"42","author":"SM Altawalbeh","year":"2024","unstructured":"Altawalbeh SM, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, et al. Cost-effectiveness of an in-development adult-formulated 21-valent pneumococcal conjugate vaccine in US adults aged 50\u00a0years or older. Vaccine. 2024;42:3024\u201332. https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.002.","journal-title":"Vaccine"},{"key":"621_CR20","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jval.2024.02.021","volume":"27","author":"SM Altawalbeh","year":"2024","unstructured":"Altawalbeh SM, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, et al. Pneumococcal vaccination strategies in 50-year-olds to decrease racial disparities: a US societal perspective cost-effectiveness analysis. Value Health. 2024;27:721\u20139. https:\/\/doi.org\/10.1016\/j.jval.2024.02.021.","journal-title":"Value Health"},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/13696998.2024.2404331","volume":"27","author":"FP Alvarez","year":"2024","unstructured":"Alvarez FP, Allard L, Bianic F, Bricout H, Cr\u00e9pey P, Gaillat J, et al. Cost-effectiveness and public health impact of using high dose quadrivalent influenza vaccine in the French older adults population. J Med Econ. 2024;27:1300\u20137. https:\/\/doi.org\/10.1080\/13696998.2024.2404331.","journal-title":"J Med Econ"},{"key":"621_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vhri.2020.11.006","volume":"25","author":"A Amiche","year":"2021","unstructured":"Amiche A, Tanriover MD, Bellier L, Ugur B, Akin L. Cost utility of switching from trivalent to quadrivalent influenza vaccine in Turkey. Value Health Reg Issues. 2021;25:15\u201322. https:\/\/doi.org\/10.1016\/j.vhri.2020.11.006.","journal-title":"Value Health Reg Issues"},{"key":"621_CR23","doi-asserted-by":"publisher","first-page":"756","DOI":"10.17269\/s41997-018-0050-9","volume":"109","author":"M Atwood","year":"2018","unstructured":"Atwood M, Beausoleil L, Breton M-C, Laferriere C, Sato R, Weycker D. Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults. Can J Public Health. 2018;109:756\u201368. https:\/\/doi.org\/10.17269\/s41997-018-0050-9.","journal-title":"Can J Public Health"},{"key":"621_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2024.2436183","volume":"24","author":"A Averin","year":"2025","unstructured":"Averin A, Huebbe B, Atwood M, Bayer LJ, Lade C, von Eiff C, et al. Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany. Expert Rev Vaccines. 2025;24:1\u201310. https:\/\/doi.org\/10.1080\/14760584.2024.2436183.","journal-title":"Expert Rev Vaccines"},{"key":"621_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12916-015-0452-y","volume":"13","author":"M Baguelin","year":"2015","unstructured":"Baguelin M, Camacho A, Flasche S, Edmunds WJ. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study. BMC Med. 2015;13:236. https:\/\/doi.org\/10.1186\/s12916-015-0452-y.","journal-title":"BMC Med"},{"key":"621_CR26","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.amepre.2020.10.022","volume":"60","author":"SM Bartsch","year":"2021","unstructured":"Bartsch SM, O\u2019Shea KJ, Wedlock PT, Ferguson MC, Siegmund SS, Lee BY. Potential clinical and economic value of Norovirus vaccination in the community setting. Am J Prev Med. 2021;60:360\u20138. https:\/\/doi.org\/10.1016\/j.amepre.2020.10.022.","journal-title":"Am J Prev Med"},{"key":"621_CR27","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1016\/j.vaccine.2021.05.084","volume":"39","author":"L Bellier","year":"2021","unstructured":"Bellier L, Petitjean A, Sarazu T, Tresierra J, Lopez JG. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme. Vaccine. 2021;39:4144\u201352. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.084.","journal-title":"Vaccine"},{"key":"621_CR28","doi-asserted-by":"publisher","first-page":"2050653","DOI":"10.1080\/21645515.2022.2050653","volume":"18","author":"PM Bianculli","year":"2022","unstructured":"Bianculli PM, Bellier L, Mangado IO, P\u00e9rez CG, Mieres G, Lazarov L, et al. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis. Hum Vaccin Immunother. 2022;18:2050653. https:\/\/doi.org\/10.1080\/21645515.2022.2050653.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR29","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.vaccine.2016.03.003","volume":"34","author":"A Blommaert","year":"2016","unstructured":"Blommaert A, Bilcke J, Willem L, Verhaegen J, Goossens H, Beutels P. The cost-effectiveness of pneumococcal vaccination in healthy adults over 50: an exploration of influential factors for Belgium. Vaccine. 2016;34:2106\u201312. https:\/\/doi.org\/10.1016\/j.vaccine.2016.03.003.","journal-title":"Vaccine"},{"key":"621_CR30","doi-asserted-by":"publisher","first-page":"699","DOI":"10.4161\/hv.23268","volume":"9","author":"S Boccalini","year":"2013","unstructured":"Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013;9:699\u2013706. https:\/\/doi.org\/10.4161\/hv.23268.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/11594030-000000000-00000","volume":"32","author":"L Brydak","year":"2012","unstructured":"Brydak L, Roiz J, Faivre P, Reygrobellet C. Implementing an influenza vaccination programme for adults aged \u226565 years in Poland: a cost-effectiveness analysis. Clin Drug Investig. 2012;32:73\u201385. https:\/\/doi.org\/10.2165\/11594030-000000000-00000.","journal-title":"Clin Drug Investig"},{"key":"621_CR32","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1080\/21645515.2018.1438792","volume":"14","author":"S Capri","year":"2018","unstructured":"Capri S, Barbieri M, de Waure C, Boccalini S, Panatto D. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population. Hum Vaccin Immunother. 2018;14:1331\u201341. https:\/\/doi.org\/10.1080\/21645515.2018.1438792.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR33","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.vaccine.2018.03.006","volume":"36","author":"C Chen","year":"2018","unstructured":"Chen C, Beutels P, Newall AT. Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. Vaccine. 2018;36:2057\u201360. https:\/\/doi.org\/10.1016\/j.vaccine.2018.03.006.","journal-title":"Vaccine"},{"key":"621_CR34","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1016\/j.vaccine.2018.08.084","volume":"36","author":"C Chen","year":"2018","unstructured":"Chen C, Beutels P, Wood J, Menzies R, MacIntyre CR, McIntyre P, et al. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia. Vaccine. 2018;36:6307\u201313. https:\/\/doi.org\/10.1016\/j.vaccine.2018.08.084.","journal-title":"Vaccine"},{"key":"621_CR35","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.vaccine.2018.01.052","volume":"36","author":"C Chen","year":"2018","unstructured":"Chen C, Wood JG, Beutels P, Menzies R, MacIntyre CR, Dirmesropian S, et al. The role of timeliness in the cost-effectiveness of older adult vaccination: a case study of pneumococcal conjugate vaccine in Australia. Vaccine. 2018;36:1265\u201371. https:\/\/doi.org\/10.1016\/j.vaccine.2018.01.052.","journal-title":"Vaccine"},{"key":"621_CR36","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.vaccine.2021.03.041","volume":"39","author":"D Chen","year":"2021","unstructured":"Chen D, Ye Z, Pi Z, Mizukami S, Aoyagi K, Jiang Y. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China. Vaccine. 2021;39:2237\u201345. https:\/\/doi.org\/10.1016\/j.vaccine.2021.03.041.","journal-title":"Vaccine"},{"key":"621_CR37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12325-014-0115-y","volume":"31","author":"J Chen","year":"2014","unstructured":"Chen J, O\u2019Brien MA, Yang HK, Grabenstein JD, Dasbach EJ. Cost-effectiveness of pneumococcal vaccines for adults in the United States. Adv Ther. 2014;31:392\u2013409. https:\/\/doi.org\/10.1007\/s12325-014-0115-y.","journal-title":"Adv Ther"},{"key":"621_CR38","doi-asserted-by":"publisher","first-page":"e0133606","DOI":"10.1371\/journal.pone.0133606","volume":"10","author":"A Chit","year":"2015","unstructured":"Chit A, Roiz J, Aballea S. An assessment of the expected cost-effectiveness of quadrivalent influenza vaccines in Ontario, Canada using a static model. PLoS ONE. 2015;10:e0133606. https:\/\/doi.org\/10.1371\/journal.pone.0133606.","journal-title":"PLoS ONE"},{"key":"621_CR39","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.vaccine.2014.10.079","volume":"33","author":"A Chit","year":"2015","unstructured":"Chit A, Roiz J, Briquet B, Greenberg DP. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine. 2015;33:734\u201341. https:\/\/doi.org\/10.1016\/j.vaccine.2014.10.079.","journal-title":"Vaccine"},{"key":"621_CR40","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1016\/j.vaccine.2020.05.065","volume":"38","author":"EJ Choi","year":"2020","unstructured":"Choi EJ, Park JH, Chun BC. Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea. Vaccine. 2020;38:5002\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.065.","journal-title":"Vaccine"},{"key":"621_CR41","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/vaccines10030445","volume":"10","author":"MJ Choi","year":"2022","unstructured":"Choi MJ, Shin G, Kang D, Lim J-O, Kim Y-K, Choi WS, et al. Cost-effectiveness of influenza vaccination strategies in adults: older adults aged \u226565 years, adults aged 50\u201364 years, and at-risk adults aged 19\u201364 years. Vaccines. 2022;10:445. https:\/\/doi.org\/10.3390\/vaccines10030445.","journal-title":"Vaccines"},{"key":"621_CR42","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1080\/21645515.2018.1456602","volume":"14","author":"M-J Choi","year":"2018","unstructured":"Choi M-J, Kang S-O, Oh J-J, Park S-B, Kim M-J, Cheong H-J. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea. Hum Vaccin Immunother. 2018;14:1914\u201322. https:\/\/doi.org\/10.1080\/21645515.2018.1456602.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR43","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1016\/j.vaccine.2024.05.001","volume":"42","author":"G Danelian","year":"2024","unstructured":"Danelian G, Burton L, Bayley T, Sanchez-Marroquin A, Park J, Manley H, et al. The impact and cost-effectiveness of pneumococcal immunisation strategies for the elderly in England. Vaccine. 2024;42:3838\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2024.05.001.","journal-title":"Vaccine"},{"key":"621_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12916-024-03277-3","volume":"22","author":"PT de Boer","year":"2024","unstructured":"de Boer PT, van Werkhoven CH, van Hoek AJ, Knol MJ, Sanders EAM, Wallinga J, et al. Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands. BMC Med. 2024;22:69. https:\/\/doi.org\/10.1186\/s12916-024-03277-3.","journal-title":"BMC Med"},{"key":"621_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1080\/13696998.2025.2488151","volume":"28","author":"C de Courville","year":"2025","unstructured":"de Courville C, Tadera C, Arashiro T, Bianic F, Costa M, Joshi M, et al. Cost-effectiveness and public health impact of using high dose influenza vaccine in the Japanese older adults. J Med Econ. 2025;28:544\u201355. https:\/\/doi.org\/10.1080\/13696998.2025.2488151.","journal-title":"J Med Econ"},{"key":"621_CR46","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/eurpub\/ckz041","volume":"29","author":"C de Waure","year":"2019","unstructured":"de Waure C, Boccalini S, Bonanni P, Amicizia D, Poscia A, Bechini A, et al. Adjuvanted influenza vaccine for the Italian elderly in the 2018\/19 season: an updated health technology assessment. Eur J Public Health. 2019;29:900\u20135. https:\/\/doi.org\/10.1093\/eurpub\/ckz041.","journal-title":"Eur J Public Health"},{"key":"621_CR47","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.vaccine.2022.01.033","volume":"40","author":"H Ding","year":"2022","unstructured":"Ding H, Huang J, Ngai CH, Sun Q, Kwok K-O, Wang HH, et al. The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65\u00a0years: a comparative modelling study. Vaccine. 2022;40:1282\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.033.","journal-title":"Vaccine"},{"key":"621_CR48","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1016\/j.vaccine.2017.06.085","volume":"35","author":"S Dirmesropian","year":"2017","unstructured":"Dirmesropian S, Wood JG, MacIntyre CR, Beutels P, McIntyre P, Menzies R, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine. 2017;35:4307\u201314. https:\/\/doi.org\/10.1016\/j.vaccine.2017.06.085.","journal-title":"Vaccine"},{"key":"621_CR49","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/03007995.2021.1914942","volume":"37","author":"M Dronova","year":"2021","unstructured":"Dronova M, Ikeoka H, Itsumura N, Hirotsu N, Ansaripour A, Aball\u00e9a S, et al. Cost-effectiveness of baloxavir marboxil compared with laninamivir for the treatment of influenza in patients at high risk for complications in Japan. Curr Med Res Opin. 2021;37:1135\u201348. https:\/\/doi.org\/10.1080\/03007995.2021.1914942.","journal-title":"Curr Med Res Opin"},{"key":"621_CR50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.vaccine.2020.11.028","volume":"39","author":"I Edoka","year":"2021","unstructured":"Edoka I, Kohli-Lynch C, Fraser H, Hofman K, Tempia S, McMorrow M, et al. A cost-effectiveness analysis of South Africa\u2019s seasonal influenza vaccination programme. Vaccine. 2021;39:412\u201322. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.028.","journal-title":"Vaccine"},{"key":"621_CR51","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/vaccines10081360","volume":"10","author":"A Fochesato","year":"2022","unstructured":"Fochesato A, Sottile S, Pugliese A, M\u00e1rquez-Pel\u00e1ez S, Toro-Diaz H, Gani R, et al. An economic evaluation of the adjuvanted quadrivalent influenza vaccine compared with standard-dose quadrivalent influenza vaccine in the Spanish older adult population. Vaccines. 2022;10:1360. https:\/\/doi.org\/10.3390\/vaccines10081360.","journal-title":"Vaccines"},{"key":"621_CR52","doi-asserted-by":"publisher","first-page":"igy035","DOI":"10.1093\/geroni\/igy035","volume":"2","author":"G France","year":"2018","unstructured":"France G, Wateska AR, Nowalk MP, DePasse J, Raviotta JM, Shim E, et al. Potential cost-effectiveness of a universal influenza vaccine in older adults. Innov Aging. 2018;2:igy035. https:\/\/doi.org\/10.1093\/geroni\/igy035.","journal-title":"Innov Aging"},{"key":"621_CR53","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1080\/14760584.2024.2417854","volume":"23","author":"G Gavazzi","year":"2024","unstructured":"Gavazzi G, Paccalin M, Berkovitch Q, Leleu H, Moreau R, Ciglia E, et al. Cost-effectiveness of cell-based influenza vaccine in France. Expert Rev Vaccines. 2024;23:1020\u20138. https:\/\/doi.org\/10.1080\/14760584.2024.2417854.","journal-title":"Expert Rev Vaccines"},{"key":"621_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14760584.2025.2488495","volume":"24","author":"GB Gebretekle","year":"2025","unstructured":"Gebretekle GB, O\u2019Reilly R, Mac S, Fadel S, Crowcroft NS, Sander B. Economic analysis of 15-valent and 20-valent pneumococcal conjugate vaccines among older adults in Ontario, Canada. Expert Rev Vaccines. 2025;24:1\u201310. https:\/\/doi.org\/10.1080\/14760584.2025.2488495.","journal-title":"Expert Rev Vaccines"},{"key":"621_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12111232","author":"G Gourzoulidis","year":"2024","unstructured":"Gourzoulidis G, Tzanetakos C, Solakidi A, Markatis E, Detsis M, Mendes D, et al. Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Greece. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12111232.","journal-title":"Vaccines"},{"key":"621_CR56","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.4161\/hv.21571","volume":"8","author":"P Grzesiowski","year":"2012","unstructured":"Grzesiowski P, Aguiar-Ib\u00e1\u00f1ez R, Kobry\u0144 A, Durand L, Puig P-E. Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland. Hum Vaccin Immunother. 2012;8:1382\u201394. https:\/\/doi.org\/10.4161\/hv.21571.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR57","doi-asserted-by":"publisher","first-page":"04126","DOI":"10.7189\/jogh.14.04126","volume":"14","author":"MZ Hassan","year":"2024","unstructured":"Hassan MZ, Jubayer Biswas MAA, Shirin T, Rahman M, Chowdhury F, Azziz-Baumgartner E, et al. Cost-effectiveness of seasonal influenza vaccination in WHO-defined high-risk populations in Bangladesh. J Glob Health. 2024;14:04126. https:\/\/doi.org\/10.7189\/jogh.14.04126.","journal-title":"J Glob Health"},{"key":"621_CR58","doi-asserted-by":"publisher","first-page":"e0177342","DOI":"10.1371\/journal.pone.0177342","volume":"12","author":"JY Heo","year":"2017","unstructured":"Heo JY, Seo YB, Choi WS, Lee J, Noh JY, Jeong HW, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS ONE. 2017;12:e0177342. https:\/\/doi.org\/10.1371\/journal.pone.0177342.","journal-title":"PLoS ONE"},{"key":"621_CR59","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.vaccine.2021.12.002","volume":"40","author":"WL Herring","year":"2022","unstructured":"Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2022;40:483\u201393. https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.002.","journal-title":"Vaccine"},{"key":"621_CR60","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12916-020-01802-8","volume":"18","author":"D Hodgson","year":"2020","unstructured":"Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE. Evaluating the next generation of RSV intervention strategies: a mathematical modelling study and cost-effectiveness analysis. BMC Med. 2020;18:348. https:\/\/doi.org\/10.1186\/s12916-020-01802-8.","journal-title":"BMC Med"},{"key":"621_CR61","doi-asserted-by":"publisher","first-page":"e0139140","DOI":"10.1371\/journal.pone.0139140","volume":"10","author":"S Hoshi","year":"2015","unstructured":"Hoshi S, Kondo M, Okubo I. Economic evaluation of immunisation programme of 23-valent pneumococcal polysaccharide vaccine and the inclusion of 13-valent pneumococcal conjugate vaccine in the list for single-dose subsidy to the elderly in Japan. PLoS ONE. 2015;10:e0139140. https:\/\/doi.org\/10.1371\/journal.pone.0139140.","journal-title":"PLoS ONE"},{"key":"621_CR62","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.1016\/j.vaccine.2022.10.010","volume":"40","author":"S-L Hoshi","year":"2022","unstructured":"Hoshi S-L, Shono A, Seposo X, Okubo R, Kondo M. Cost-effectiveness analyses of 15- and 20-valent pneumococcal conjugate vaccines for Japanese elderly. Vaccine. 2022;40:7057\u201364. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.010.","journal-title":"Vaccine"},{"key":"621_CR63","doi-asserted-by":"publisher","first-page":"126294","DOI":"10.1016\/j.vaccine.2024.126294","volume":"42","author":"DW Hutton","year":"2024","unstructured":"Hutton DW, Prosser LA, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, et al. Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus. Vaccine. 2024;42:126294. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126294.","journal-title":"Vaccine"},{"key":"621_CR64","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1080\/14760584.2021.1952869","volume":"20","author":"A Igarashi","year":"2021","unstructured":"Igarashi A, Hirose E, Kobayashi Y, Yonemoto N, Lee B. Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Rev Vaccines. 2021;20:1153\u201365. https:\/\/doi.org\/10.1080\/14760584.2021.1952869.","journal-title":"Expert Rev Vaccines"},{"key":"621_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1053\/j.ajkd.2019.01.025","volume":"74","author":"J Ishigami","year":"2019","unstructured":"Ishigami J, Padula WV, Grams ME, Chang AR, Jaar B, Gansevoort RT, et al. Cost-effectiveness of pneumococcal vaccination among patients with CKD in the United States. Am J Kidney Dis. 2019;74:23\u201335. https:\/\/doi.org\/10.1053\/j.ajkd.2019.01.025.","journal-title":"Am J Kidney Dis"},{"key":"621_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040753","author":"J Jacob","year":"2023","unstructured":"Jacob J, Biering-S\u00f8rensen T, Holger Ehlers L, Edwards CH, Mohn KG, Nilsson A, et al. Cost-effectiveness of vaccination of older adults with an MF59(\u00ae)-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in Denmark, Norway, and Sweden. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11040753.","journal-title":"Vaccines"},{"key":"621_CR67","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.vaccine.2019.11.045","volume":"38","author":"M Jiang","year":"2020","unstructured":"Jiang M, Li P, Wang W, Zhao M, Atif N, Zhu S, et al. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China. Vaccine. 2020;38:1057\u201364. https:\/\/doi.org\/10.1016\/j.vaccine.2019.11.045.","journal-title":"Vaccine"},{"key":"621_CR68","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1080\/13696998.2018.1465272","volume":"21","author":"Y Jiang","year":"2018","unstructured":"Jiang Y, Yang X, Taniguchi K, Petigara T, Abe M. A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan. J Med Econ. 2018;21:687\u201397. https:\/\/doi.org\/10.1080\/13696998.2018.1465272.","journal-title":"J Med Econ"},{"key":"621_CR69","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.vaccine.2024.01.031","volume":"42","author":"DW Kang","year":"2024","unstructured":"Kang DW, Kim CR, Song JY, Park SK. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Vaccine. 2024;42:871\u20138. https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.031.","journal-title":"Vaccine"},{"key":"621_CR70","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1016\/j.vaccine.2023.04.069","volume":"41","author":"E Kim DeLuca","year":"2023","unstructured":"Kim DeLuca E, Gebremariam A, Rose A, Biggerstaff M, Meltzer MI, Prosser LA. Cost-effectiveness of routine annual influenza vaccination by age and risk status. Vaccine. 2023;41:4239\u201348. https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.069.","journal-title":"Vaccine"},{"key":"621_CR71","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s40273-018-0715-5","volume":"36","author":"Y-K Kim","year":"2018","unstructured":"Kim Y-K, Song JY, Jang H, Kim TH, Koo H, Varghese L, et al. Cost effectiveness of quadrivalent influenza vaccines compared with trivalent influenza vaccines in young children and older adults in Korea. Pharmacoeconomics. 2018;36:1475\u201390. https:\/\/doi.org\/10.1007\/s40273-018-0715-5.","journal-title":"Pharmacoeconomics"},{"key":"621_CR72","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/vaccines10091386","volume":"10","author":"MA Kohli","year":"2022","unstructured":"Kohli MA, Maschio M, Cartier S, Mould-Quevedo J, Fricke F-U. The cost-effectiveness of vaccination of older adults with an MF59-adjuvanted quadrivalent influenza vaccine compared to other available quadrivalent vaccines in Germany. Vaccines. 2022;10:1386. https:\/\/doi.org\/10.3390\/vaccines10091386.","journal-title":"Vaccines"},{"key":"621_CR73","doi-asserted-by":"publisher","first-page":"2432745","DOI":"10.1080\/21645515.2024.2432745","volume":"20","author":"EM La","year":"2024","unstructured":"La EM, Graham J, Singer D, Molnar D, Poston S, Curran D, et al. Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged \u226560 years in the United States. Hum Vaccin Immunother. 2024;20:2432745. https:\/\/doi.org\/10.1080\/21645515.2024.2432745.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR74","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1016\/j.vaccine.2009.02.024","volume":"27","author":"BY Lee","year":"2009","unstructured":"Lee BY, Ercius AK, Smith KJ. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine. 2009;27:2251\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2009.02.024.","journal-title":"Vaccine"},{"key":"621_CR75","doi-asserted-by":"publisher","first-page":"e11284","DOI":"10.1371\/journal.pone.0011284","volume":"5","author":"BY Lee","year":"2010","unstructured":"Lee BY, McGlone SM, Bailey RR, Wiringa AE, Zimmer SM, Smith KJ, et al. To test or to treat? An analysis of influenza testing and antiviral treatment strategies using economic computer modeling. PLoS ONE. 2010;5:e11284. https:\/\/doi.org\/10.1371\/journal.pone.0011284.","journal-title":"PLoS ONE"},{"key":"621_CR76","doi-asserted-by":"publisher","first-page":"7110","DOI":"10.1016\/j.vaccine.2009.09.056","volume":"27","author":"BY Lee","year":"2009","unstructured":"Lee BY, Tai JHY, Bailey RR, Smith KJ. The timing of influenza vaccination for older adults (65 years and older). Vaccine. 2009;27:7110\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2009.09.056.","journal-title":"Vaccine"},{"key":"621_CR77","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1016\/j.vaccine.2016.04.008","volume":"34","author":"M-K Leung","year":"2016","unstructured":"Leung M-K, You JHS. Cost-effectiveness of an influenza vaccination program offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly. Vaccine. 2016;34:2469\u201376. https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.008.","journal-title":"Vaccine"},{"key":"621_CR78","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12916-025-03970-x","volume":"23","author":"X Li","year":"2025","unstructured":"Li X, Willem L, Johannesen CK, Urchuegu\u00eda-Fornes A, Lehtonen T, Osei-Yeboah R, et al. Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis. BMC Med. 2025;23:170. https:\/\/doi.org\/10.1186\/s12916-025-03970-x.","journal-title":"BMC Med"},{"key":"621_CR79","first-page":"e30","volume":"19","author":"CJ Lin","year":"2013","unstructured":"Lin CJ, Zimmerman RK, Smith KJ. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. Am J Manag Care. 2013;19:e30-37.","journal-title":"Am J Manag Care"},{"key":"621_CR80","doi-asserted-by":"publisher","first-page":"e4445","DOI":"10.1136\/bmj.e4445","volume":"345","author":"AK Lugn\u00e9r","year":"2012","unstructured":"Lugn\u00e9r AK, van Boven M, de Vries R, Postma MJ, Wallinga J. Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis. BMJ. 2012;345:e4445. https:\/\/doi.org\/10.1136\/bmj.e4445.","journal-title":"BMJ"},{"key":"621_CR81","doi-asserted-by":"publisher","first-page":"e0242255","DOI":"10.1371\/journal.pone.0242255","volume":"15","author":"S Mac","year":"2020","unstructured":"Mac S, O\u2019Reilly R, Adhikari NKJ, Fowler R, Sander B. Point-of-care diagnostic tests for influenza in the emergency department: a cost-effectiveness analysis in a high-risk population from a Canadian perspective. PLoS ONE. 2020;15:e0242255. https:\/\/doi.org\/10.1371\/journal.pone.0242255.","journal-title":"PLoS ONE"},{"key":"621_CR82","doi-asserted-by":"publisher","first-page":"100826","DOI":"10.1016\/j.epidem.2025.100826","volume":"51","author":"R Manansala","year":"2025","unstructured":"Manansala R, Bilcke J, Willem L, Hens N, Beutels P. Optimizing influenza vaccine allocation by age using cost-effectiveness analysis: a comparison of 6720 vaccination program scenarios in children and adults in Belgium. Epidemics. 2025;51:100826. https:\/\/doi.org\/10.1016\/j.epidem.2025.100826.","journal-title":"Epidemics"},{"key":"621_CR83","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1183\/13993003.00325-2015","volume":"46","author":"M-JJ Mangen","year":"2015","unstructured":"Mangen M-JJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46:1407\u201316. https:\/\/doi.org\/10.1183\/13993003.00325-2015.","journal-title":"Eur Respir J"},{"key":"621_CR84","doi-asserted-by":"publisher","first-page":"e0199427","DOI":"10.1371\/journal.pone.0199427","volume":"13","author":"S Marbaix","year":"2018","unstructured":"Marbaix S, Peetermans WE, Verhaegen J, Annemans L, Sato R, Mignon A, et al. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PLoS ONE. 2018;13:e0199427. https:\/\/doi.org\/10.1371\/journal.pone.0199427.","journal-title":"PLoS ONE"},{"key":"621_CR85","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3111\/13696998.2015.1044456","volume":"18","author":"G Meier","year":"2015","unstructured":"Meier G, Gregg M, Poulsen Nautrup B. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K. J Med Econ. 2015;18:746\u201361. https:\/\/doi.org\/10.3111\/13696998.2015.1044456.","journal-title":"J Med Econ"},{"key":"621_CR86","doi-asserted-by":"publisher","first-page":"6254","DOI":"10.1016\/j.vaccine.2013.10.023","volume":"31","author":"MJ Meijboom","year":"2013","unstructured":"Meijboom MJ, Pouwels KB, Luytjes W, Postma MJ, Hak E. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population. Vaccine. 2013;31:6254\u201360. https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.023.","journal-title":"Vaccine"},{"key":"621_CR87","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1080\/14737167.2022.2134120","volume":"22","author":"D Mendes","year":"2022","unstructured":"Mendes D, Averin A, Atwood M, Sato R, Vyse A, Campling J, et al. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease. Expert Rev Pharmacoecon Outcomes Res. 2022;22:1285\u201395. https:\/\/doi.org\/10.1080\/14737167.2022.2134120.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"621_CR88","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1080\/21645515.2018.1469368","volume":"14","author":"FS Mennini","year":"2018","unstructured":"Mennini FS, Bini C, Marcellusi A, Rinaldi A, Franco E. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy. Hum Vaccin Immunother. 2018;14:1867\u201373. https:\/\/doi.org\/10.1080\/21645515.2018.1469368.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR89","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1016\/j.vaccine.2011.02.098","volume":"29","author":"CI Michaelidis","year":"2011","unstructured":"Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine. 2011;29:3525\u201330. https:\/\/doi.org\/10.1016\/j.vaccine.2011.02.098.","journal-title":"Vaccine"},{"key":"621_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jval.2012.11.009","volume":"16","author":"CI Michaelidis","year":"2013","unstructured":"Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Cost-effectiveness of a program to eliminate disparities in pneumococcal vaccination rates in elderly minority populations: an exploratory analysis. Value Health. 2013;16:311\u20137. https:\/\/doi.org\/10.1016\/j.jval.2012.11.009.","journal-title":"Value Health"},{"key":"621_CR91","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/1471-2458-14-718","volume":"14","author":"CI Michaelidis","year":"2014","unstructured":"Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Cost-effectiveness of programs to eliminate disparities in elderly vaccination rates in the United States. BMC Public Health. 2014;14:718. https:\/\/doi.org\/10.1186\/1471-2458-14-718.","journal-title":"BMC Public Health"},{"key":"621_CR92","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1080\/14760584.2024.2410898","volume":"23","author":"A Mizukami","year":"2024","unstructured":"Mizukami A, Preckler V, Verelst F, Matsuki T, Ho Y, Kurai D, et al. Cost-effectiveness analysis of respiratory syncytial virus vaccination with the adjuvanted prefusion F protein vaccine (RSVPreF3 OA) for adults \u226560 years old in Japan. Expert Rev Vaccines. 2024;23:986\u201396. https:\/\/doi.org\/10.1080\/14760584.2024.2410898.","journal-title":"Expert Rev Vaccines"},{"key":"621_CR93","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/cid\/ciad658","volume":"78","author":"SM Moghadas","year":"2024","unstructured":"Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, et al. Cost-effectiveness of Prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States. Clin Infect Dis. 2024;78:1328\u201335. https:\/\/doi.org\/10.1093\/cid\/ciad658.","journal-title":"Clin Infect Dis"},{"key":"621_CR94","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1080\/13696998.2024.2445429","volume":"28","author":"PP Mueller","year":"2025","unstructured":"Mueller PP, Tajima A, Cassell K, Matsuki T, Cossrow N, Yi Z, et al. Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approach. J Med Econ. 2025;28:136\u201345. https:\/\/doi.org\/10.1080\/13696998.2024.2445429.","journal-title":"J Med Econ"},{"key":"621_CR95","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/14760584.2024.2350246","volume":"23","author":"S Nakamura","year":"2024","unstructured":"Nakamura S, Mikami M, Hayamizu T, Yonemoto N, Moyon C, Gouldson M, et al. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan. Expert Rev Vaccines. 2024;23:546\u201360. https:\/\/doi.org\/10.1080\/14760584.2024.2350246.","journal-title":"Expert Rev Vaccines"},{"key":"621_CR96","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.vaccine.2014.01.017","volume":"32","author":"AT Newall","year":"2014","unstructured":"Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory analysis of the vaccine efficacy required. Vaccine. 2014;32:1323\u20135. https:\/\/doi.org\/10.1016\/j.vaccine.2014.01.017.","journal-title":"Vaccine"},{"key":"621_CR97","doi-asserted-by":"publisher","first-page":"1071117","DOI":"10.3389\/fpubh.2023.1071117","volume":"11","author":"T Ngamprasertchai","year":"2023","unstructured":"Ngamprasertchai T, Kositamongkol C, Lawpoolsri S, Rattanaumpawan P, Luvira V, Chongtrakool P, et al. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult. Front Public Health. 2023;11:1071117. https:\/\/doi.org\/10.3389\/fpubh.2023.1071117.","journal-title":"Front Public Health"},{"key":"621_CR98","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1016\/j.vaccine.2020.02.081","volume":"38","author":"VH Nguyen","year":"2020","unstructured":"Nguyen VH, Vizzotti C, Uruena A, Giglio N, Magneres C, Richmond H. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina. Vaccine. 2020;38:3682\u20139. https:\/\/doi.org\/10.1016\/j.vaccine.2020.02.081.","journal-title":"Vaccine"},{"key":"621_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11050933","author":"VH Nguyen","year":"2023","unstructured":"Nguyen VH, Ashraf M, Mould-Quevedo JF. Cost-effectiveness of the use of adjuvanted quadrivalent seasonal influenza vaccine in older adults in Ireland. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11050933.","journal-title":"Vaccines"},{"key":"621_CR100","doi-asserted-by":"publisher","first-page":"2266233","DOI":"10.1080\/21645515.2023.2266233","volume":"19","author":"E Nham","year":"2023","unstructured":"Nham E, Seong H, Hyun H, Yoon JG, Noh JY, Cheong HJ, et al. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate. Hum Vaccin Immunother. 2023;19:2266233. https:\/\/doi.org\/10.1080\/21645515.2023.2266233.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR101","doi-asserted-by":"publisher","first-page":"126107","DOI":"10.1016\/j.vaccine.2024.07.008","volume":"42","author":"MP Nowalk","year":"2024","unstructured":"Nowalk MP, Smith KJ, Raviotta JM, Wateska A, Zimmerman RK. Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age. Vaccine. 2024;42:126107. https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.008.","journal-title":"Vaccine"},{"key":"621_CR102","doi-asserted-by":"publisher","first-page":"2101333","DOI":"10.1080\/21645515.2022.2101333","volume":"18","author":"LS Nymark","year":"2022","unstructured":"Nymark LS, Dag Berild J, Lyngstad TM, Askeland Winje B, Frimann Vestrheim D, Aaberge I, et al. Cost-utility analysis of the universal pneumococcal vaccination programme for older adults in Norway. Hum Vaccines Immunother. 2022;18:2101333. https:\/\/doi.org\/10.1080\/21645515.2022.2101333.","journal-title":"Hum Vaccines Immunother"},{"key":"621_CR103","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1016\/j.vaccine.2024.04.016","volume":"42","author":"K Owusu-Edusei","year":"2024","unstructured":"Owusu-Edusei K, Favre-Bulle A, Tsoumani E, Mutschler T, Cossrow N. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65\u00a0years-and-above in Switzerland. Vaccine. 2024;42:3239\u201346. https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.016.","journal-title":"Vaccine"},{"key":"621_CR104","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/vaccines11010161","volume":"11","author":"Z Pi","year":"2023","unstructured":"Pi Z, Aoyagi K, Arima K, Wu X, Ye Z, Jiang Y. Optimization of elderly influenza and pneumococcal immunization programs in Beijing, China using health economic evaluations: a modeling study. Vaccines. 2023;11:161. https:\/\/doi.org\/10.3390\/vaccines11010161.","journal-title":"Vaccines"},{"key":"621_CR105","doi-asserted-by":"publisher","first-page":"127184","DOI":"10.1016\/j.vaccine.2025.127184","volume":"56","author":"JG Pitter","year":"2025","unstructured":"Pitter JG, Mihajlovi\u0107 J, Nagy D, van der Schans J, Vok\u00f3 Z, Kal\u00f3 Z. Underreported influenza mortality in Central and Eastern Europe hinders the extension of seasonal influenza vaccination programs in older adults. Vaccine. 2025;56:127184. https:\/\/doi.org\/10.1016\/j.vaccine.2025.127184.","journal-title":"Vaccine"},{"key":"621_CR106","doi-asserted-by":"publisher","first-page":"e22308","DOI":"10.1371\/journal.pone.0022308","volume":"6","author":"LA Prosser","year":"2011","unstructured":"Prosser LA, Lavelle TA, Fiore AE, Bridges CB, Reed C, Jain S, et al. Cost-effectiveness of 2009 pandemic influenza A(H1N1) vaccination in the United States. PLoS ONE. 2011;6:e22308. https:\/\/doi.org\/10.1371\/journal.pone.0022308.","journal-title":"PLoS ONE"},{"key":"621_CR107","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.japh.2019.02.011","volume":"59","author":"GR Pullagura","year":"2019","unstructured":"Pullagura GR, Waite NM, Houle SKD, Violette R, Wong WWL. Cost-utility analysis of offering a novel remunerated community pharmacist consultation service on influenza vaccination for seniors in Ontario, Canada. J Am Pharm Assoc. 2019;59:489-497.e1. https:\/\/doi.org\/10.1016\/j.japh.2019.02.011.","journal-title":"J Am Pharm Assoc"},{"key":"621_CR108","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1111\/jgs.14323","volume":"64","author":"JM Raviotta","year":"2016","unstructured":"Raviotta JM, Smith KJ, DePasse J, Brown ST, Shim E, Nowalk MP, et al. Cost-effectiveness and public health effect of influenza vaccine strategies for U.S. elderly adults. J Am Geriatr Soc. 2016;64:2126\u201331. https:\/\/doi.org\/10.1111\/jgs.14323.","journal-title":"J Am Geriatr Soc"},{"key":"621_CR109","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40121-024-00972-9","volume":"13","author":"L Rey-Ares","year":"2024","unstructured":"Rey-Ares L, Averin A, Mac Mullen M, Hariharan D, Atwood M, Carballo C, et al. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Argentinean adults. Infect Dis Ther. 2024;13:1235\u201351. https:\/\/doi.org\/10.1007\/s40121-024-00972-9.","journal-title":"Infect Dis Ther"},{"key":"621_CR110","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40261-015-0345-z","volume":"36","author":"JM Rodr\u00edguez Gonz\u00e1lez-Moro","year":"2016","unstructured":"Rodr\u00edguez Gonz\u00e1lez-Moro JM, Men\u00e9ndez R, Campins M, Lwoff N, Oyag\u00fcez I, Echave M, et al. Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+ years in Spain. Clin Drug Investig. 2016;36:41\u201353. https:\/\/doi.org\/10.1007\/s40261-015-0345-z.","journal-title":"Clin Drug Investig"},{"key":"621_CR111","doi-asserted-by":"publisher","first-page":"126567","DOI":"10.1016\/j.vaccine.2024.126567","volume":"44","author":"M Rosenthal","year":"2025","unstructured":"Rosenthal M, Stoecker C, Leidner AJ, Cho BH, Pilishvili T, Kobayashi M. Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for U.S. adults aged 65 years and older and adults 19 years and older with underlying conditions. Vaccine. 2025;44:126567. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126567.","journal-title":"Vaccine"},{"key":"621_CR112","doi-asserted-by":"publisher","first-page":"321","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00007","volume":"139","author":"MB Rothberg","year":"2003","unstructured":"Rothberg MB, Bellantonio S, Rose DN. Management of influenza in adults older than 65 years of age: cost-effectiveness of rapid testing and antiviral therapy. Ann Intern Med. 2003;139:321\u20139. https:\/\/doi.org\/10.7326\/0003-4819-139-5_Part_1-200309020-00007.","journal-title":"Ann Intern Med"},{"key":"621_CR113","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.clinthera.2010.06.016","volume":"32","author":"MH Rozenbaum","year":"2010","unstructured":"Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands. Clin Ther. 2010;32:1517\u201332. https:\/\/doi.org\/10.1016\/j.clinthera.2010.06.016.","journal-title":"Clin Ther"},{"key":"621_CR114","doi-asserted-by":"publisher","first-page":"54","DOI":"10.14745\/ccdr.v51i23a01","volume":"51","author":"M Rudd","year":"2025","unstructured":"Rudd M, Simmons AE, Gebretekle GB, Tuite AR. Cost-effectiveness of respiratory syncytial virus vaccination strategies for older Canadian adults: a multi-model comparison. Can Commun Dis Rep. 2025;51:54\u201367. https:\/\/doi.org\/10.14745\/ccdr.v51i23a01.","journal-title":"Can Commun Dis Rep"},{"key":"621_CR115","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020427","author":"J Ruiz-Arag\u00f3n","year":"2023","unstructured":"Ruiz-Arag\u00f3n J, M\u00e1rquez-Pel\u00e1ez S. An economic comparison in the elderly of adjuvanted quadrivalent influenza vaccine with recombinant quadrivalent influenza vaccine in Spain. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11020427.","journal-title":"Vaccines"},{"key":"621_CR116","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3390\/vaccines10020176","volume":"10","author":"J Ruiz-Arag\u00f3n","year":"2022","unstructured":"Ruiz-Arag\u00f3n J, M\u00e1rquez-Pel\u00e1ez S, Gani R, Alvarez P, Guerrero-Luduena R. Cost-effectiveness and burden of disease for adjuvanted quadrivalent influenza vaccines compared to high-dose quadrivalent influenza vaccines in elderly patients in Spain. Vaccines. 2022;10:176. https:\/\/doi.org\/10.3390\/vaccines10020176.","journal-title":"Vaccines"},{"key":"621_CR117","doi-asserted-by":"publisher","first-page":"1200116","DOI":"10.3389\/fpubh.2023.1200116","volume":"11","author":"F Rumi","year":"2023","unstructured":"Rumi F, Basile M, Cicchetti A, Alvarez FP, Azzi MV, Muzii B. Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population. Front Public Health. 2023;11:1200116. https:\/\/doi.org\/10.3389\/fpubh.2023.1200116.","journal-title":"Front Public Health"},{"key":"621_CR118","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.vaccine.2022.01.015","volume":"40","author":"FG Sandmann","year":"2022","unstructured":"Sandmann FG, van Leeuwen E, Bernard-Stoecklin S, Casado I, Castilla J, Domegan L, et al. Health and economic impact of seasonal influenza mass vaccination strategies in European settings: a mathematical modelling and cost-effectiveness analysis. Vaccine. 2022;40:1306\u201315. https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.015.","journal-title":"Vaccine"},{"key":"621_CR119","doi-asserted-by":"publisher","first-page":"101095","DOI":"10.1016\/j.vhri.2025.101095","volume":"47","author":"J Santiaguel","year":"2025","unstructured":"Santiaguel J, Averin A, Nua W, Atwood M, Huang L, Hariharan D, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine among adults in the Philippines. Value Health Reg Issues. 2025;47:101095. https:\/\/doi.org\/10.1016\/j.vhri.2025.101095.","journal-title":"Value Health Reg Issues"},{"key":"621_CR120","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.vaccine.2024.02.041","volume":"42","author":"A Shoukat","year":"2024","unstructured":"Shoukat A, Bawden CE, R\u00f6st G, LeBlanc JJ, Galvani AP, Langley JM, et al. Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: a Canadian Immunization Research Network (CIRN) study. Vaccine. 2024;42:1768\u201376. https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.041.","journal-title":"Vaccine"},{"key":"621_CR121","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/s0002-9343(02)01222-6","volume":"113","author":"KJ Smith","year":"2002","unstructured":"Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med. 2002;113:300\u20137. https:\/\/doi.org\/10.1016\/s0002-9343(02)01222-6.","journal-title":"Am J Med"},{"key":"621_CR122","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1001\/jama.2012.169","volume":"307","author":"KJ Smith","year":"2012","unstructured":"Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA. 2012;307:804\u201312. https:\/\/doi.org\/10.1001\/jama.2012.169.","journal-title":"JAMA"},{"key":"621_CR123","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amepre.2012.11.035","volume":"44","author":"KJ Smith","year":"2013","unstructured":"Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med. 2013;44:373\u201381. https:\/\/doi.org\/10.1016\/j.amepre.2012.11.035.","journal-title":"Am J Prev Med"},{"key":"621_CR124","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.amepre.2021.01.023","volume":"61","author":"KJ Smith","year":"2021","unstructured":"Smith KJ, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, et al. Higher-valency pneumococcal conjugate vaccines: an exploratory cost-effectiveness analysis in U.S. seniors. Am J Prev Med. 2021;61:28\u201336. https:\/\/doi.org\/10.1016\/j.amepre.2021.01.023.","journal-title":"Am J Prev Med"},{"key":"621_CR125","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1016\/j.vaccine.2021.06.037","volume":"39","author":"KJ Smith","year":"2021","unstructured":"Smith KJ, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, et al. Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysis. Vaccine. 2021;39:4278\u201382. https:\/\/doi.org\/10.1016\/j.vaccine.2021.06.037.","journal-title":"Vaccine"},{"key":"621_CR126","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s40121-022-00669-x","volume":"11","author":"KJ Smith","year":"2022","unstructured":"Smith KJ, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, et al. Cost-Effectiveness of Newly recommended pneumococcal vaccination strategies in older underserved minority adults in the USA. Infect Dis Ther. 2022;11:1683\u201393. https:\/\/doi.org\/10.1007\/s40121-022-00669-x.","journal-title":"Infect Dis Ther"},{"key":"621_CR127","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.vaccine.2008.01.007","volume":"26","author":"KJ Smith","year":"2008","unstructured":"Smith KJ, Zimmerman RK, Lin CJ, Nowalk MP, Ko F-S, McEllistrem MC, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008;26:1420\u201331. https:\/\/doi.org\/10.1016\/j.vaccine.2008.01.007.","journal-title":"Vaccine"},{"key":"621_CR128","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1016\/j.vaccine.2009.03.059","volume":"27","author":"KJ Smith","year":"2009","unstructured":"Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS. Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: a cost-effectiveness analysis. Vaccine. 2009;27:3159\u201364. https:\/\/doi.org\/10.1016\/j.vaccine.2009.03.059.","journal-title":"Vaccine"},{"issue":"4","key":"621_CR129","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/jgs.14588","volume":"65","author":"KJ Smith","year":"2017","unstructured":"Smith KJ, Zimmerman RK, Nowalk MP, Lin CJ. Cost\u2010effectiveness of the 4 pillars practice transformation program to improve vaccination of adults aged 65 and older. J Am Geriatr Soc. 2017;65(4):763\u20138. https:\/\/doi.org\/10.1111\/jgs.14588.","journal-title":"J Am Geriatr Soc"},{"key":"621_CR130","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.amepre.2024.11.014","volume":"68","author":"KJ Smith","year":"2025","unstructured":"Smith KJ, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, et al. Cost-effectiveness and public health impact of 24-valent pneumococcal conjugate vaccine compared with the recommended pneumococcal vaccines in older adults. Am J Prev Med. 2025;68:518\u201326. https:\/\/doi.org\/10.1016\/j.amepre.2024.11.014.","journal-title":"Am J Prev Med"},{"key":"621_CR131","doi-asserted-by":"publisher","first-page":"2348124","DOI":"10.1080\/21645515.2024.2348124","volume":"20","author":"Y Song","year":"2024","unstructured":"Song Y, Shim E. Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea. Hum Vaccin Immunother. 2024;20:2348124. https:\/\/doi.org\/10.1080\/21645515.2024.2348124.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR132","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1016\/j.vaccine.2012.03.031","volume":"30","author":"Y Song","year":"2012","unstructured":"Song Y, Tai JHY, Bartsch SM, Zimmerman RK, Muder RR, Lee BY. The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients. Vaccine. 2012;30:3675\u201382. https:\/\/doi.org\/10.1016\/j.vaccine.2012.03.031.","journal-title":"Vaccine"},{"key":"621_CR133","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s11606-016-3651-0","volume":"31","author":"C Stoecker","year":"2016","unstructured":"Stoecker C, Kim L, Gierke R, Pilishvili T. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States. J Gen Intern Med. 2016;31:901\u20138. https:\/\/doi.org\/10.1007\/s11606-016-3651-0.","journal-title":"J Gen Intern Med"},{"key":"621_CR134","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.vaccine.2019.12.029","volume":"38","author":"C Stoecker","year":"2020","unstructured":"Stoecker C, Kobayashi M, Matanock A, Cho B-H, Pilishvili T. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020;38:1770\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.029.","journal-title":"Vaccine"},{"key":"621_CR135","doi-asserted-by":"publisher","first-page":"647725","DOI":"10.3389\/fpubh.2021.647725","volume":"9","author":"X Sun","year":"2021","unstructured":"Sun X, Tang Y, Ma X, Guo X, Huang Z, Ren J, et al. Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine program for the elderly aged 60 years or older in Shanghai, China. Front Public Health. 2021;9:647725. https:\/\/doi.org\/10.3389\/fpubh.2021.647725.","journal-title":"Front Public Health"},{"key":"621_CR136","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2146\/ajhp080296","volume":"66","author":"SE Talbird","year":"2009","unstructured":"Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health-Syst Pharm. 2009;66:469\u201380. https:\/\/doi.org\/10.2146\/ajhp080296.","journal-title":"Am J Health-Syst Pharm"},{"key":"621_CR137","doi-asserted-by":"publisher","first-page":"iii","DOI":"10.3310\/hta13110","volume":"13","author":"P Tappenden","year":"2009","unstructured":"Tappenden P, Jackson R, Cooper K, Rees A, Simpson E, Read R, et al. Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess. 2009;13:iii-1\u2013246. https:\/\/doi.org\/10.3310\/hta13110.","journal-title":"Health Technol Assess"},{"key":"621_CR138","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/vaccines10081285","volume":"10","author":"D Tavares","year":"2022","unstructured":"Tavares D, Mouri\u00f1o H, Rodr\u00edguez CA, Saborido CM. Cost effectiveness of quadrivalent versus trivalent inactivated influenza vaccines for the Portuguese elderly population. Vaccines. 2022;10:1285. https:\/\/doi.org\/10.3390\/vaccines10081285.","journal-title":"Vaccines"},{"key":"621_CR139","doi-asserted-by":"publisher","first-page":"e0192640","DOI":"10.1371\/journal.pone.0192640","volume":"13","author":"D Thorrington","year":"2018","unstructured":"Thorrington D, van Rossum L, Knol M, de Melker H, R\u00fcmke H, Hak E, et al. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PLoS ONE. 2018;13:e0192640. https:\/\/doi.org\/10.1371\/journal.pone.0192640.","journal-title":"PLoS ONE"},{"key":"621_CR140","doi-asserted-by":"publisher","first-page":"E989","DOI":"10.1503\/cmaj.240452","volume":"196","author":"AR Tuite","year":"2024","unstructured":"Tuite AR, Simmons AE, Rudd M, Cernat A, Gebretekle GB, Yeung MW, et al. Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis. CMAJ Can Med Assoc J J Assoc Medicale Can. 2024;196:E989-1005. https:\/\/doi.org\/10.1503\/cmaj.240452.","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can"},{"key":"621_CR141","doi-asserted-by":"publisher","first-page":"100587","DOI":"10.1016\/j.jvacx.2024.100587","volume":"21","author":"A Urue\u00f1a","year":"2024","unstructured":"Urue\u00f1a A, Micone P, Mould-Quevedo J, Saenz C, Delgado M, Montes JL, et al. The clinical and economic value of enhanced influenza vaccines for the elderly in Argentina. Vaccine X. 2024;21:100587. https:\/\/doi.org\/10.1016\/j.jvacx.2024.100587.","journal-title":"Vaccine X"},{"key":"621_CR142","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/vaccines9040335","volume":"9","author":"A Urue\u00f1a","year":"2021","unstructured":"Urue\u00f1a A, Micone P, Magneres C, Mould-Quevedo J, Giglio N. Cost-effectiveness analysis of switching from trivalent to quadrivalent seasonal influenza vaccine in Argentina. Vaccines. 2021;9:335. https:\/\/doi.org\/10.3390\/vaccines9040335.","journal-title":"Vaccines"},{"key":"621_CR143","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s10198-024-01683-1","volume":"25","author":"S van der Pol","year":"2024","unstructured":"van der Pol S, Postma MJ, Boersma C. Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the Netherlands. Eur J Health Econ. 2024;25:1557\u201367. https:\/\/doi.org\/10.1007\/s10198-024-01683-1.","journal-title":"Eur J Health Econ"},{"key":"621_CR144","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1016\/j.vaccine.2024.04.040","volume":"42","author":"S van der Pol","year":"2024","unstructured":"van der Pol S, Zeevat F, Postma MJ, Boersma C. Cost-effectiveness of high-dose influenza vaccination in the Netherlands: incorporating the impact on both respiratory and cardiovascular hospitalizations. Vaccine. 2024;42:3429\u201336. https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.040.","journal-title":"Vaccine"},{"key":"621_CR145","doi-asserted-by":"publisher","first-page":"e0149540","DOI":"10.1371\/journal.pone.0149540","volume":"11","author":"AJ van Hoek","year":"2016","unstructured":"van Hoek AJ, Miller E. Cost-Effectiveness of vaccinating immunocompetent \u226565 year olds with the 13-valent pneumococcal conjugate vaccine in England. PLoS ONE. 2016;11:e0149540. https:\/\/doi.org\/10.1371\/journal.pone.0149540.","journal-title":"PLoS ONE"},{"key":"621_CR146","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101605","author":"Y Wang","year":"2023","unstructured":"Wang Y, Fekadu G, You JHS. Comparative cost-effectiveness analysis of respiratory syncytial virus vaccines for older adults in Hong Kong. Vaccines. 2023. https:\/\/doi.org\/10.3390\/vaccines11101605.","journal-title":"Vaccines"},{"key":"621_CR147","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.amepre.2019.10.022","volume":"58","author":"AR Wateska","year":"2020","unstructured":"Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, et al. Pneumococcal vaccination in adults aged \u226565 years: cost-effectiveness and health impact in U.S. populations. Am J Prev Med. 2020;58:487\u201395. https:\/\/doi.org\/10.1016\/j.amepre.2019.10.022.","journal-title":"Am J Prev Med"},{"key":"621_CR148","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1016\/j.vaccine.2022.10.066","volume":"40","author":"AR Wateska","year":"2022","unstructured":"Wateska AR, Patricia Nowalk M, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, et al. Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-old. Vaccine. 2022;40:7312\u201320. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.066.","journal-title":"Vaccine"},{"key":"621_CR149","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1111\/jgs.19031","volume":"72","author":"AR Wateska","year":"2024","unstructured":"Wateska AR, Nowalk MP, Altawalbeh SM, Lin CJ, Harrison LH, Schaffner W, et al. Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults. J Am Geriatr Soc. 2024;72:2423\u201333. https:\/\/doi.org\/10.1111\/jgs.19031.","journal-title":"J Am Geriatr Soc"},{"key":"621_CR150","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1016\/j.vaccine.2023.06.007","volume":"41","author":"AR Wateska","year":"2023","unstructured":"Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK, et al. Cost-effectiveness of an in-development adult-formulated pneumococcal vaccine in older US adults. Vaccine. 2023;41:4431\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.007.","journal-title":"Vaccine"},{"key":"621_CR151","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1080\/21645515.2018.1428507","volume":"14","author":"L Willem","year":"2018","unstructured":"Willem L, Blommaert A, Hanquet G, Thiry N, Bilcke J, Theeten H, et al. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Hum Vaccin Immunother. 2018;14:1218\u201329. https:\/\/doi.org\/10.1080\/21645515.2018.1428507.","journal-title":"Hum Vaccin Immunother"},{"key":"621_CR152","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.1016\/j.vaccine.2020.05.072","volume":"38","author":"E Wolff","year":"2020","unstructured":"Wolff E, Storsaeter J, \u00d6rtqvist \u00c5, Naucler P, Larsson S, Lepp T, et al. Cost-effectiveness of pneumococcal vaccination for elderly in Sweden. Vaccine. 2020;38:4988\u201395. https:\/\/doi.org\/10.1016\/j.vaccine.2020.05.072.","journal-title":"Vaccine"},{"key":"621_CR153","doi-asserted-by":"publisher","first-page":"126985","DOI":"10.1016\/j.vaccine.2025.126985","volume":"54","author":"R Ximenes","year":"2025","unstructured":"Ximenes R, Simmons AE, Gebretekle GB, Nam A, Wong E, Salvadori MI, et al. Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada. Vaccine. 2025;54:126985. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126985.","journal-title":"Vaccine"},{"key":"621_CR154","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.ajic.2019.05.003","volume":"47","author":"N Xing","year":"2019","unstructured":"Xing N, Cheung W-Y, Jiang M, You JHS. Standing orders program of pneumococcal vaccination for hospitalized elderly patients in Hong Kong: a cost-effectiveness analysis. Am J Infect Control. 2019;47:1302\u20138. https:\/\/doi.org\/10.1016\/j.ajic.2019.05.003.","journal-title":"Am J Infect Control"},{"key":"621_CR155","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12916-020-01545-6","volume":"18","author":"J Yang","year":"2020","unstructured":"Yang J, Atkins KE, Feng L, Baguelin M, Wu P, Yan H, et al. Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60\u00a0years and above in mainland China: a modelling analysis. BMC Med. 2020;18:90. https:\/\/doi.org\/10.1186\/s12916-020-01545-6.","journal-title":"BMC Med"},{"key":"621_CR156","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1136\/jech.2008.081885","volume":"63","author":"JHS You","year":"2009","unstructured":"You JHS, Wong WCW, Ip M, Lee NLS, Ho SC. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. J Epidemiol Community Health. 2009;63:906\u201311. https:\/\/doi.org\/10.1136\/jech.2008.081885.","journal-title":"J Epidemiol Community Health"},{"key":"621_CR157","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/s12879-014-0618-9","volume":"14","author":"JHS You","year":"2014","unstructured":"You JHS, Ming W, Chan PKS. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014;14:618. https:\/\/doi.org\/10.1186\/s12879-014-0618-9.","journal-title":"BMC Infect Dis"},{"key":"621_CR158","doi-asserted-by":"publisher","first-page":"e0182091","DOI":"10.1371\/journal.pone.0182091","volume":"12","author":"JHS You","year":"2017","unstructured":"You JHS, Tam L-P, Lee NLS. Cost-effectiveness of molecular point-of-care testing for influenza viruses in elderly patients at ambulatory care setting. PLoS ONE. 2017;12:e0182091. https:\/\/doi.org\/10.1371\/journal.pone.0182091.","journal-title":"PLoS ONE"},{"key":"621_CR159","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.jval.2019.07.001","volume":"22","author":"M Yue","year":"2019","unstructured":"Yue M, Dickens BL, Yoong JS-Y, I-Cheng Chen M, Teerawattananon Y, Cook AR. Cost-effectiveness analysis for influenza vaccination coverage and timing in tropical and subtropical climate settings: a modeling study. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2019;22:1345\u201354. https:\/\/doi.org\/10.1016\/j.jval.2019.07.001.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"621_CR160","doi-asserted-by":"publisher","first-page":"e0209643","DOI":"10.1371\/journal.pone.0209643","volume":"14","author":"J-W Yun","year":"2019","unstructured":"Yun J-W, Choi MJ, Shin G-S, Lim J-O, Noh JY, Kim Y-K, et al. Cost-effectiveness of influenza vaccine strategies for the elderly in South Korea. PLoS ONE. 2019;14:e0209643. https:\/\/doi.org\/10.1371\/journal.pone.0209643.","journal-title":"PLoS ONE"},{"key":"621_CR161","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/infdis\/jiab118","volume":"226","author":"F Zeevat","year":"2022","unstructured":"Zeevat F, Luttjeboer J, Paulissen JHJ, van der Schans J, Beutels P, Boersma C, et al. Exploratory analysis of the economically justifiable price of a hypothetical RSV vaccine for older adults in the Netherlands and the United Kingdom. J Infect Dis. 2022;226:S102. https:\/\/doi.org\/10.1093\/infdis\/jiab118.","journal-title":"J Infect Dis"},{"key":"621_CR162","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1016\/j.vaccine.2016.11.003","volume":"34","author":"D Zhao","year":"2016","unstructured":"Zhao D, Gai Tobe R, Cui M, He J, Wu B. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine. 2016;34:6158\u201365. https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.003.","journal-title":"Vaccine"},{"key":"621_CR163","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","volume":"38","author":"TO Tengs","year":"2000","unstructured":"Tengs TO, Wallace A. One Thousand Health-Related Quality-of-Life Estimates. Med Care. 2000;38:583\u2013637.","journal-title":"Med Care"},{"key":"621_CR164","unstructured":"Ara R, Brazier J, Lloyd A, Chevrou-S\u00e9verac H. How health state utilities used in cost-effectiveness models are currently identified, reviewed and reported. Value Outcomes Spotlight. 2018. p. 31\u20133."},{"key":"621_CR165","unstructured":"Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. Inst. Clin. Res. Health Policy Stud. Tufts Med. Cent. [cited 2025 Aug 25]. www.cearegistry.org. Accessed 25 Aug 2025"},{"key":"621_CR166","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/0272989X19837969","volume":"39","author":"F Xie","year":"2019","unstructured":"Xie F, Zoratti M, Chan K, Husereau D, Krahn M, Levine O, et al. Toward a centralized, systematic approach to the identification, appraisal, and use of health state utility values for reimbursement decision making: introducing the health utility book (HUB). Med Decis Making. 2019;39:371\u20139. https:\/\/doi.org\/10.1177\/0272989X19837969.","journal-title":"Med Decis Making"},{"key":"621_CR167","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40273-021-01039-0","volume":"39","author":"MJ Zoratti","year":"2021","unstructured":"Zoratti MJ, Chan KKW, Husereau D, Krahn M, Levine M, Thabane L, et al. Towards transparency in the selection of published health utility inputs in cost-utility analyses: the health utility application tool (HAT). Pharmacoeconomics. 2021;39:1075\u201384. https:\/\/doi.org\/10.1007\/s40273-021-01039-0.","journal-title":"Pharmacoeconomics"},{"key":"621_CR168","doi-asserted-by":"publisher","first-page":"238146831985259","DOI":"10.1177\/2381468319852594","volume":"4","author":"MJ Zoratti","year":"2019","unstructured":"Zoratti MJ, Zhou T, Chan K, Levine O, Krahn M, Husereau D, et al. Health utility book (HUB)-Cancer: protocol for a systematic literature review of health state utility values in cancer. MDM Policy Practice. 2019;4:2381468319852594. https:\/\/doi.org\/10.1177\/2381468319852594.","journal-title":"MDM Policy Practice"},{"key":"621_CR169","unstructured":"Pham T, Mihajlovi\u0107 J, Lon\u010dar I, Zeevat F, Meszaros K, Pham T, et al. Health state utility values used in published cost-utility analyses. OSF; 2025 [cited 2025 Oct 21]; https:\/\/osf.io\/w7xm2. Accessed 21 Oct 2025"},{"key":"621_CR170","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1473-3099(05)70142-0","volume":"5","author":"PW Stone","year":"2005","unstructured":"Stone PW, Schackman BR, Neukermans CP, Olchanski N, Greenberg D, Rosen AB, et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis. 2005;5:383\u201391. https:\/\/doi.org\/10.1016\/S1473-3099(05)70142-0.","journal-title":"Lancet Infect Dis"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00621-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00621-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:45:47Z","timestamp":1773841547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00621-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":170,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00621-y","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"THP, TAP, AW, and BKC declare no conflict of interest. JM and IL are employed by Mihajlovi\u0107 Health Analytics. FZ and JvdS are employed by Health-Ecore, TAP is employed by the University of Sydney Vietnam Institute. KM was employed by GlaxoSmithKline Biologicals (GSK).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication (from patients\/participants)"}}]}}